When it approved Avonex in May , the FDA said both Biogen 's product and Betaseron were developed under the incentives of the Ophran Drug Act which provides seven years of marketing exclusivity for products that treat rare diseases .
<response> When it approved <misc>Avonex</misc> in May , the <organization>FDA</organization> said both <organization>Biogen</organization> 's product and <misc>Betaseron</misc> were developed under the incentives of the <misc>Ophran Drug Act</misc> which provides seven years of marketing exclusivity for products that treat rare diseases . </response>